Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 190

The DOI matches its Crossref record.

From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis

Open access
Armstrong, April W., Siegel, Michael P., Bagel, Jerry, Boh, Erin E., Buell, Megan, Cooper, Kevin D., Callis Duffin, Kristina, Eichenfield, Lawrence F., Garg, Amit, Gelfand, Joel M., Gottlieb, Alice B., Koo, John Y.M., Korman, Neil J., Krueger, Gerald G., Lebwohl, Mark G., Leonardi, Craig L., Mandelin, Arthur M., Menter, M. Alan, Merola, Joseph F., Pariser, David M., Prussick, Ronald B., Ryan, Caitriona, Shah, Kara N., Weinberg, Jeffrey M., Williams, MaryJane O.U., Wu, Jashin J., Yamauchi, Paul S., Van Voorhees, Abby S. · 2017 · Journal of the American Academy of Dermatology

Abstract

BACKGROUND: An urgent need exists in the United States to establish treatment goals in psoriasis. OBJECTIVE: We aim to establish defined treatment targets toward which clinicians and patients with psoriasis can strive to inform treatment decisions, reduce disease burden, and improve outcomes in practice. METHODS: The National Psoriasis Foundation conducted a consensus-building study among psoriasis experts using the Delphi method. The process consisted of: (1) literature review, (2) pre-Delphi question selection and input from general dermatologists and patients, and (3) 4 Delphi rounds. RESULTS: A total of 25 psoriasis experts participated in the Delphi process. The most preferred instrument was body surface area (BSA). The most preferred time for evaluating patient response after starting new therapies was at 3 months. The acceptable response at 3 months postinitiation was either BSA 3% or less or BSA improvement 75% or more from baseline. The target response at 3 months postinitiation was BSA 1% or less. During the maintenance period, evaluation every 6 months was most preferred. The target response at every 6 months maintenance evaluation is BSA 1% or less. LIMITATIONS: Although BSA is feasible in practice, it does not encompass health-related quality of life, costs, and risks of side effects. CONCLUSION: With defined treatment targets, clinicians and patients can regularly evaluate treatment responses and perform benefit-risk assessments of therapeutic options individualized to the patient.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaad.2016.10.017

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 190

Metadata

Authors
Armstrong, A. W., Siegel, M. P., Bagel, J., Boh, E. E., Buell, M., Cooper, K. D., Callis Duffin, K., Eichenfield, L. F., Garg, A., Gelfand, J. M., Gottlieb, A. B., Koo, J. Y. M., Korman, N. J., Krueger, G. G., Lebwohl, M. G., Leonardi, C. L., Mandelin, A. M., Menter, M. A., Merola, J. F., Pariser, D. M., Prussick, R. B., Ryan, C., Shah, K. N., Weinberg, J. M., Williams, M. O. U., Wu, J. J., Yamauchi, P. S., & Van Voorhees, A. S.
Venue
Journal of the American Academy of Dermatology
Publisher
Elsevier BV
Published
2017-02
Volume
76
Issue
2
Pages
290-298
ISSN
0190-9622 (ISSN-L)
OpenAlex
W2558385573
Cited by
190
References
0
FWCI
8.58
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. https://app.cochat.ai/papers/10.1016/j.jaad.2016.10.017
The paper
Armstrong, A. W., Siegel, M. P., Bagel, J., Boh, E. E., Buell, M., Cooper, K. D., Callis Duffin, K., Eichenfield, L. F., Garg, A., Gelfand, J. M., Gottlieb, A. B., Koo, J. Y. M., Korman, N. J., Krueger, G. G., Lebwohl, M. G., Leonardi, C. L., Mandelin, A. M., Menter, M. A., Merola, J. F., . . . Van Voorhees, A. S. (2017). From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2016.10.017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.